Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 7 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 4 completed trials have results

Key Signals

2 recruiting

Enrollment Performance

Analytics

N/A
7(100.0%)
7Total
N/A(7)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (7)

Showing 7 of 7 trials
NCT02539966Not ApplicableCompleted

Safety & Performance Study of the FANTOM Sirolimus-Eluting Bioresorbable Coronary Scaffold

Role: lead

NCT05406622Not ApplicableRecruiting

MOTIV BTK Randomized Controlled Trial

Role: lead

NCT03587922Not ApplicableRecruiting

FANTOM Post Market Clinical Trial

Role: lead

NCT02512003Not ApplicableCompleted

Pilot Study of the Fantom Bioresorbable Scaffold (FANTOM I)

Role: lead

NCT01262703Not ApplicableCompleted

Safety Study of a Bioresorbable Coronary Stent

Role: lead

NCT01845311Not ApplicableCompleted

ReZolve2 Clinical Investigation

Role: lead

NCT04591938Not ApplicableUnknown

FANTOM ENCORE Sirolimus-eluting Bioresorbable Scaffold for Treatment of De-novo CAD: the ENCORE-I Study

Role: collaborator

All 7 trials loaded